Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Cancer (CRC): early-phase trial registry
15 of 20 indexed Colorectal Cancer (CRC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 15 currently recruiting · #848 of 28,707 conditions by registered trial count
Colorectal Cancer (CRC): 20 US clinical trials tracked, 15 recruiting.
Colorectal Cancer (CRC) is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Revolution Medicines, running 5 of these trials.
Enrollment posture brief
Registry condition colorectal-cancer-crc
OPEN 15 | RECR 75% | LATE 1 | EARLY 18 | RANK #848 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Colorectal Cancer (CRC) lists 15 open slots (75% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colorectal Cancer (CRC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Cancer (CRC) is recruiting above its size-band peers.
15 of 20 indexed trials (75%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Colorectal Cancer (CRC) research.
Revolution Medicines accounts for 5 of 20 trials (25%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Cancer (CRC) enrolment sits around 300 participants.
Median target enrolment is 300 among the 20 trials that report a genuine target (sentinel values excluded). 4 of those (20%) plan for fewer than 100 participants.
-
Colorectal Cancer (CRC) research is mostly interventional.
19 interventional and 1 observational studies make up this index (95% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
Collection of Samples USOPTIVAL Study
Universal Diagnostics
NCT04792684
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines
NCT05379985
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines
NCT06040541
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
Evaluation of Gixam's Performance in a FIT Negative Population
Jubaan
NCT06612281
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines
NCT07397338
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation
NCT05824975
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
NCT06026410
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
NCT07223047
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT06789172
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
HonorHealth Research Institute
NCT07463599
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT04969315
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT07321106
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations
NCT07011576
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT04083599
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines
NCT05462717
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Amgen
NCT05198934
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
NCT02955940
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
NCT03314935
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Colorectal Cancer (CRC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colorectal Cancer (CRC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colorectal Cancer (CRC) page
20 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Colorectal Cancer (CRC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Revolution Medicines sponsors the most Colorectal Cancer (CRC) trials on record, review their full trial history before evaluating a specific study. See Revolution Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer (CRC) condition card totals 20 registered trials; most-linked intervention RMC-6236; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.